title: Successful treatment of heart transplant rejection with photopheresis.
abstract: Photopheresis is a potential therapy for rejection in which reinfusion of mononuclear cells exposed to ultraviolet-A light ex vivo, after treatment with 8-methoxypsoralen in vivo, initiates host immune responses that specifically inhibit the cytotoxicity of the photomodulated mononuclear cells. Between May 1990 and January 1991, 7 heart transplant (HT) patients (age 42.2 +/- 16.7 [mean +/- SD] years) on triple immunosuppression (cyclosporine, corticosteroids, and azathioprine) had 9 episodes of non-hemodynamically compromising moderate rejection that were treated with photopheresis. These episodes of rejection occurred at an average of 114.4 +/- 180.5 (range 8-575) days after HT. After oral administration the mean serum level of 8-methoxypsoralen achieved was 129.0 +/- 72.4 ng/ml. An average of 10.4 +/- 9.6 x 10(9) mononuclear cells were treated with each photopheresis procedure. Photopheresis was performed twice when less than 5 x 10(9) mononuclear cells had been treated with the first procedure. Of 9 rejection episodes treated with photopheresis, 5 required 1 procedure and 4 required 2 procedures. Photopheresis was used to treat a single episode of rejection in 5 pts. and 2 separate rejection episodes in 2 additional pts. Eight of 9 episodes of rejection were successfully reversed by photopheresis as assessed by endomyocardial biopsy (EMB) performed 7 days after treatment. Immunohistochemical analysis of EMB samples revealed that postphotopheresis cell counts for T cells, B cells, and macrophages were reduced compared to pretreatment values and correlated with the histopathologic resolution of rejection. Hemodynamics were normal prephotopheresis and remained unchanged at the time when the postphotopheresis EMB showed no evidence rejection No adverse effects have been observed with photopheresis. Over a follow-up period of 5.3 +/- 4.0 months, rejection and infection rates/pt./follow-up months were 0.3 +/- 0.4 and 0.04 +/- 0.07, respectively. The preliminary, short term results of this pilot study indicate that photopheresis may be efficacious in the treatment of moderate rejection in hemodynamically stable HT patients and thus may be an alternative to corticosteroid pulses.
authors.affiliation: Department of Medicine, Loyola University of Chicago, Maywood, Illinois 60153.
authors.forename: M R
authors.initials: MR
authors.lastname: Costanzo-Nordin
authors.forename: E A
authors.initials: EA
authors.lastname: Hubbell
authors.forename: E J
authors.initials: EJ
authors.lastname: O'Sullivan
authors.forename: M R
authors.initials: MR
authors.lastname: Johnson
authors.forename: G M
authors.initials: GM
authors.lastname: Mullen
authors.forename: A L
authors.initials: AL
authors.lastname: Heroux
authors.forename: W G
authors.initials: WG
authors.lastname: Kao
authors.forename: B M
authors.initials: BM
authors.lastname: McManus
authors.forename: R
authors.initials: R
authors.lastname: Pifarre
authors.forename: J A
authors.initials: JA
authors.lastname: Robinson
mesh_terms: D000328:Adult; D001781:Blood Component Removal / Q000379:methods*; D001803:Blood Transfusion; D005260:Female; D006084:Graft Rejection; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D008214:Lymphocytes / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D011701:PUVA Therapy; D011948:Receptors, Antigen, T-Cell / Q000502:physiology
chemical_list: D016853:Muromonab-CD3; D011948:Receptors, Antigen, T-Cell